Demand
← 실적 발표
01
02
03
04 05 06
톤
A1 A2 A3 A4
GILD
FY2025 Q4
개선
Gilead Sciences, Inc. 실적 발표
Buzzberg 분석
Yes2Go is expected to ramp steeply in 2026 toward blockbuster status.
Gilead reported solid FY2025 results, beating top-line guidance on strong HIV sales, with Yes2Go already hitting 90% payer coverage. Management gave a bullish 2026 outlook, including $29.6-30B total sales, an ~$800M Yes2Go ramp, and four potential launches. They also guided KITE cell therapy down ~10% due to competition and clinical trial headwinds. Yes2Go achieved 90% payer coverage in <6 months; $800M 2026 revenue guide implies ~5x from 2025.
Buzzberg 분석 Yes2Go is expected to ramp steeply in 2026 toward blockbuster status. Gilead reported solid FY2025 results, beating top-line guidance on strong HIV sales, with Yes2Go already hitting 90% payer coverage. Management gave a bullish 2026 outlook, including $29.6-30B total sales, an ~$800M Yes2Go ramp, and four potential launches. They also guided KITE cell therapy down ~10% due to competition and clinical trial headwinds. Yes2Go achieved 90% payer coverage in <6 months; $800M 2026 revenue guide implies ~5x from 2025. 전체 분석 보기분석 접기
Gilead reported solid FY2025 results, beating top-line guidance on strong HIV sales, with Yes2Go already hitting 90% payer coverage. Management gave a bullish 2026 outlook, including $29.6-30B total sales, an ~$800M Yes2Go ramp, and four potential launches. They also guided KITE cell therapy down ~10% due to competition and clinical trial headwinds. Yes2Go achieved 90% payer coverage in <6 months; $800M 2026 revenue guide implies ~5x from 2025.
- HIV portfolio grew 6% in 2025, despite $900M Part D redesign headwind; 2026 growth guided to ~6% with 2% policy-related headwinds.
- KITE cell therapy expected to decline ~10% in 2026 due to in-class competition and clinical trial enrollment impacts.
- Livdelzi benefited from competitor withdrawal in US PBC, reaching >50% second-line market share.
CELL_THERAPY 매출$1.8B보고값
HIV 매출$20.8B보고값
LIVER 매출$3.2B보고값
매출$7.924B보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Pipeline
Company targets four launches this year within a 10-launch pipeline through 2027.
HIV
BicLen once-daily combo could extend HIV switch leadership after H2 2026 launch.
핵심 내용 3개 더 보기
Oncology
Trodelvy is the only ADC now recommended in first- and second-line mTNBC.
Cell Therapy
AnitoCell could launch H2 2026 with a best-in-disease CAR-T profile.
Strategy
No major LOEs until 2036 underpins a secure long-term growth runway.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| CELL_THERAPY 매출 | $1.8B | 보고값 |
| HIV 매출 | $20.8B | 보고값 |
| LIVER 매출 | $3.2B | 보고값 |
| 매출 | $7.924B | 보고값 |
| 주당순이익(EPS) | $1.86 | 보고값 |
| 매출총이익률 | 79.51% | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $8.45–$8.85 | $8.65 | 신규 제시 |
| 매출 | FY2026 | $29.6B–$30B | $29.8B | 신규 제시 |
| 매출YES2GO | FY2026 | $0.8B | $0.8B | 신규 제시 |
| 매출CELL_THERAPY | FY2026 | -0.1% | -0.1% | 신규 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Upbeat
Executives highlighted strong commercial execution, early beat-and-raise dynamics, and a dense launch calendar, framing 2026 as a period of strength and growth.
아래에 언급된 기업 9개 모두 표시
기업발표 이후 수익률
경쟁사
경쟁사
Dietmar Berger
Gilead is advancing Trodelvi in combination with Merck's Keytruda (pembrolizumab), positioning both companies in the frontline TNBC market.
근거
“Trodelvi plus pembrolizumab in first-line PD-L1 positive metastatic TNBC in the second half of 2026.”
경쟁사
Dietmar Berger
Gilead implicitly compares its own twice-yearly HIV candidate (GS3242) against Shionogi's, arguing Shionogi still needs a partner for a complete regimen.
근거
“they cannot base once every six months treatment on one product only they also need a combination so we need to look at the overall development program that they have”
경쟁사
Andrew Dickinson
Gilead's BD strategy may target assets in competitive spaces like oncology, which includes Pfizer's offerings.
근거
“will continue to be active, and I'm confident that we'll add exciting new products over time”
경쟁사
Joanna Mercier
Descovy's high market share in PrEP competes against generic Truvada (Roche has a stake via Genentech).
근거
“record U.S. market share greater than 45%.”
경쟁사
Daniel O'Day
Gilead's BD focus could target RNAi or other modalities where Alnylam is a leader, though no specific deal mentioned.
근거
“we typically invest about $1 billion annually in smaller licensing deals, partnerships, and acquisitions.”
경쟁사
Daniel O'Day
Gilead's oncology pipeline competes with BioNTech's in breast cancer and solid tumors.
근거
“we have up to 10 ongoing and potential new launches through 2027”
경쟁사
Cindy Peretti
Gilead expects KITE cell therapy sales to decline ~10% in 2026, in part due to more patients going into clinical trials for competitor CAR-Ts. — Competing clinical trial sites are diverting patients away from KITE's commercial products, a unique headwind that may persist until newer KITE products launch.
근거
“our ability to serve the market at launch with 99% reliability and 16-day turnaround time, which again is very differentiated from the existing products on the market today.”
경쟁사
Gilead expects KITE cell therapy sales to decline ~10% in 2026, in part due to more patients going into clinical trials for competitor CAR-Ts. — Competing clinical trial sites are diverting patients away from KITE's commercial products, a unique headwind that may persist until newer KITE products launch.
Joanna Mercier
경쟁사
The withdrawal of Intercept's Ocaliva (obeticholic acid) from the US market is a direct tailwind for Gilead's Livdelzi in PBC.
Joanna Mercier외부 신호
공급망 알파 · 4발표 이후 수익률
Gilead says Yes2Go has achieved 90% payer coverage in under six months, faster than expected, which lowers the friction to patient conversion.
Kite's anitocel launch will rely on a 16-day manufacturing turnaround vs competitors, a critical differentiator in a market where patients are sick.
Gilead expects KITE cell therapy sales to decline ~10% in 2026, in part due to more patients going into clinical trials for competitor CAR-Ts.
Gilead expects a 2% HIV sales headwind in 2026 due to the Medicaid Drug Pricing Agreement and Affordable Care Act changes, a concrete impact of recent policy changes.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 9개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.